Evidence map›Paper›PMID 32981365›Full record

ArticleHypertension (Dallas, Tex. : 1979)2020

Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure.

Julio A Chirinos, Jordana B Cohen, Lei Zhao, Thomas Hanff, Nancy Sweitzer, James Fang, Vicente Corrales-Medina, Ron Anmar, Michael Morley, Payman Zamani and 11 more

Erratum issuedOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Proteome-Wide Genetic Investigation of Large Artery Stiffness.JACC. Basic to translational science · 2024
    Article
  11. Proteomic Associations of Adverse Outcomes in Human Heart Failure.Journal of the American Heart Association · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Circulating angiotensin converting enzyme 2 and COVID-19.World journal of clinical cases · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19).Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Julio A Chirinos *From the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Jordana B Cohen *From the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Lei ZhaoBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Thomas HanffFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Nancy SweitzerSarver Heart Institute, University of Arizona, Tuscon (N.S.).
James FangUniversity of Utah, Salt Lake City (J.F.).
Vicente Corrales-MedinaThe Ottawa Hospital Research Institute and University of Ottawa, Ontario, Canada (V.C.M.).
Ron AnmarBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Michael MorleyFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Payman ZamaniFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Priyanka BhattacharyaFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Jeff BrandimartoFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Yi JiaSomaLogic Inc, Boulder, CO (Y.J.).
Michael D BassoFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Zhaoqing WangBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Christina EbertBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Francisco Ramirez-ValleBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Peter H SchaferBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Dietmar SeiffertBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
David A GordonBristol Myers Squibb Company, Princeton, NJ (L.Z., R.A., M.D.B., Z.W., C.E., F.R.-V., P.H.S., D.S., D.A.G.).
Thomas CappolaFrom the Hospital of the University of Pennsylvania, Philadelphia (J.A.C., J.B.C., T.H., M.M., P.Z., P.B., J.B., T.C.).
Bristol-Myers Squibb (Germany) · DEHospital of the University of Pennsylvania · USUniversity of Arizona · USSomaLogic (United States) · USUniversity of Ottawa · CAUniversity of Utah · US

Funding

Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Understanding the relationship between obesity and tongue fat in humans and ratsP01HL094307 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 2009 to 2020
$23.7M
MTSS1 in Myocardial DiseaseR01HL141232 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Scott Michael Damrauer · 2019 to 2026
$4.7M
VASCULAR EFFECTS OF DIETARY SALT IN HUMANS WITH SALT-RESISTANT BPR01HL104106 · NHLBI · UNIVERSITY OF DELAWARE · PI EDWARDS, DAVID G, FARQUHAR, WILLIAM B · 2011 to 2021
$4.5M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection FractionR01HL121510 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2015 to 2019
$3.1M
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomesK23HL133843 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2016 to 2020
$945k
Cardiovascular Risk after Preeclampsia - The CRISP studyR56HL136730 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LEVINE, LISA DANIELLE · 2018 to 2018
$740k
Developing Oral LT3 Therapy for Heart FailureR61HL146390 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R, CAPPOLA, THOMAS P. · 2019 to 2019
$403k
Understanding Racial Differences in Vascular Function and Ventricular-Vascular Coupling in Heart Failure with Preserved Ejection FractionR03HL146874 · NHLBI · EMORY UNIVERSITY · PI MORRIS, ALANNA AMYRE · 2019 to 2020
$156k
NHLBI NIH HHS K23 HL133843NHLBI NIH HHS P01 HL094307NHLBI NIH HHS R01 HL104106NHLBI NIH HHS R01 HL121510NHLBI NIH HHS R01 HL141232NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R03 HL146874NHLBI NIH HHS R56 HL136730NHLBI NIH HHS R61 HL146390NIA NIH HHS R01 AG058969
6 · The paper itself

Abstract

ACE2 (angiotensin-converting enzyme 2) is a key component of the renin-angiotensin-aldosterone system. Yet, little is known about the clinical and biologic correlates of circulating ACE2 levels in humans. We assessed the clinical and proteomic correlates of plasma (soluble) ACE2 protein levels in human heart failure. We measured plasma ACE2 using a modified aptamer assay among PHFS (Penn Heart Failure Study) participants (n=2248). We performed an association study of ACE2 against ≈5000 other plasma proteins measured with the SomaScan platform. Plasma ACE2 was not associated with ACE inhibitor and angiotensin-receptor blocker use. Plasma ACE2 was associated with older age, male sex, diabetes mellitus, a lower estimated glomerular filtration rate, worse New York Heart Association class, a history of coronary artery bypass surgery, and higher pro-BNP (pro-B-type natriuretic peptide) levels. Plasma ACE2 exhibited associations with 1011 other plasma proteins. In pathway overrepresentation analyses, top canonical pathways associated with plasma ACE2 included clathrin-mediated endocytosis signaling, actin cytoskeleton signaling, mechanisms of viral exit from host cells, EIF2 (eukaryotic initiation factor 2) signaling, and the protein ubiquitination pathway. In conclusion, in humans with heart failure, plasma ACE2 is associated with various clinical factors known to be associated with severe coronavirus disease 2019 (COVID-19), including older age, male sex, and diabetes mellitus, but is not associated with ACE inhibitor and angiotensin-receptor blocker use. Plasma ACE2 protein levels are prominently associated with multiple cellular pathways involved in cellular endocytosis, exocytosis, and intracellular protein trafficking. Whether these have a causal relationship with ACE2 or are relevant to novel coronavirus-2 infection remains to be assessed in future studies.

Indexed as

Disease ProgressionAcademic Medical CentersAnalysis of VarianceAngiotensin-Converting Enzyme 2BiomarkersCohort StudiesCoronavirus InfectionsCOVID-19Disease OutbreaksFemaleHeart FailureHumansLinear ModelsMaleMiddle AgedPandemicsACE2 protein, humanAngiotensin-Converting Enzyme 2BiomarkersPeptidyl-Dipeptidase Aangiotensin–converting enzyme 2heart failureproteomicsrenin-angiotensin system

Identifiers

PMID32981365
PMCPMC10681288
OpenAlexW3088314665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.